+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Scynexis Inc - logo

SCYNEXIS is a drug development company that develops and commercializes anti-infectives to address unmet therapeutic needs. Its lead product candidate, SCY-078, is a novel and structurally distinct triterpenoid glucan synthase inhibitor. SCY-078 is in Phase 2 clinical development as an oral and intravenous drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. Founded in 1999, the company is headquartered in Jersey City, New Jersey.

Antifungals Global Market Report 2024 - Product Thumbnail Image

Antifungals Global Market Report 2024

  • Report
  • November 2023
  • 175 Pages
  • Global
From
From
Aspergillosis - Pipeline Insight, 2024 - Product Thumbnail Image

Aspergillosis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
Antifungal Drugs Market Report and Forecast 2023-2031 - Product Thumbnail Image

Antifungal Drugs Market Report and Forecast 2023-2031

  • Report
  • April 2023
  • 147 Pages
  • Global
From
From
Coccidioidomycosis - Pipeline Insight, 2024 - Product Thumbnail Image

Coccidioidomycosis - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 60 Pages
  • Global
From
Invasive Aspergillosis - Pipeline Insight, 2024 - Product Thumbnail Image

Invasive Aspergillosis - Pipeline Insight, 2024

  • Drug Pipelines
  • April 2024
  • 60 Pages
  • Global
From
From
From
Cyclophilin Inhibitor - Pipeline Insight, 2024 - Product Thumbnail Image

Cyclophilin Inhibitor - Pipeline Insight, 2024

  • Clinical Trials
  • January 2024
  • 60 Pages
  • Global
From
Systemic Inflammatory Response Syndrome - Pipeline Insight, 2024 - Product Thumbnail Image

Systemic Inflammatory Response Syndrome - Pipeline Insight, 2024

  • Clinical Trials
  • April 2024
  • 50 Pages
  • Global
From
Loading Indicator